Last SFr.88.25 CHF
Change Today -0.05 / -0.06%
Volume 3.5M
NOVN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 11:43 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kevin J. Buehler

Former Division Head of Alcon and Member of Executive Committee, Novartis AG
AgeTotal Calculated CompensationThis person is connected to 14 board members in 2 different organizations across 5 different industries.

See Board Relationships
56$7,246,858
As of Fiscal Year 2013

Background*

Mr. Kevin J. Buehler served as the President of Alcon Laboratories, Inc., a division of Novartis from April 2011 to May 1, 2014. Mr. Buehler served as the Chief Executive Officer and President of Alcon Inc., a division of Novartis from April 1, 2009 to 2011. He served as the Chief Marketing Officer of Alcon Laboratories Inc., from February 2006 to April 2009, Senior Vice President of Global Markets from January 1, 2007 to April 2009 and also served as its Chairman of ...

Read Full Background

Corporate Headquarters*

Lichtstrasse 35
Basel, Basel-Stadt 4056

Switzerland

Phone: 41 61 324 11 11
Fax: --

Board Members Memberships*

Former Division President
2009-Present
Director

Education*

Unknown/Other Education 1993
Harvard University
BS
Carroll University, Inc.
BSBA
Carroll University, Inc.

Other Affiliations*

Annual Compensation*

Salary$1,136,792
Bonus$755,700
Total Annual Compensation$1,892,492

Stock Options*

Restricted Stock Awards$5,065,291
All Other Compensation$289,075
Total Number of Options605,877

Total Compensation*

Total Annual Cash Compensation$2,181,567
Total Short Term Compensation$1,892,492
Other Long Term Compensation$5,354,366
Total Calculated Compensation$7,246,858
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.88.25 CHF -0.05

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Alan George Lafley Chairman of the Board, Chief Executive Officer, President and Member of Proxy Committee
The Procter & Gamble Company
$6.4M
Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
$1.8M
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Severin Schwan Ph.D.Chief Executive Officer and Director
Roche Holding AG
SFr.5.1M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.